Scholarlink

Background <p>Colorectal cancer (CRC) remains a significant cause of cancer-related mortality globally, primarily due to late-stage diagnoses. This study investigates the expression levels of antisense long non-coding RNAs (lncRNAs) RBM5-AS1, STEAP3-AS1, and VPS9D1-AS1 in both tissue and plasma samples from CRC patients to evaluate their potential as diagnostic biomarkers. Selection of these lncRNAs was based on prior studies indicating their dysregulation in CRC and their role in the Wnt/β-catenin signaling pathway, which modulates cell growth, apoptosis, and differentiation.</p> Materials and methods <p>This experimental study included 40 plasma samples and 10 tissue samples from CRC patients, alongside an equal number of samples from healthy controls. The expression levels of the lncRNAs and β-catenin were quantified using reverse transcription quantitative polymerase chain reaction (RT-qPCR). The diagnostic performance of these lncRNAs was evaluated through receiver operating characteristic (ROC) curve analysis on Plasma samples, which also facilitated the determination of optimal cutoff values.</p> Results <p>The expression of the β-catenin gene was significantly elevated in CRC tissues (6.78-fold increase, <i>p</i> = 0.02) and plasma samples (4.79-fold increase, <i>p</i> &lt; 0.001) compared to controls. Likewise, the expression levels of the lncRNAs were significantly higher in both CRC tissues and plasma samples relative to healthy subjects (<i>p</i> &lt; 0.001). ROC curve analysis revealed robust predictive capabilities for the plasma expression of these lncRNAs, with area under the curve (AUC) values of 0.82 for STEAP3-AS1, 0.94 for VPS9D1-AS1, and 0.83 for RBM5-AS1.</p> Conclusion <p>The findings indicate that the expression levels of β-catenin and lncRNAs STEAP3-AS1, VPS9D1-AS1, and RBM5-AS1 are significantly higher in both tissue and plasma samples from CRC patients compared to healthy individuals. Consequently, these lncRNAs may serve as promising biomarkers for CRC diagnosis. However, further studies are needed to validate these findings and explore additional applications.td</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Plasma expression of antisense LncRNAs RBM5-AS1, VPS9D1-AS1 and STEAP3-AS1 as novel biomarkers for colorectal cancer diagnosis

  • 期刊论文

  • 发表日期：

    2025年6月16日

查看全文
  • Mohammadreza Karbalaei Hashemiyan,
  • Reza Manouchehri Ardekani,
  • Mohsen Razavizade,
  • Ali Rafat,
  • Mohsen Hemmati-Dinarvand

摘要

Background

Colorectal cancer (CRC) remains a significant cause of cancer-related mortality globally, primarily due to late-stage diagnoses. This study investigates the expression levels of antisense long non-coding RNAs (lncRNAs) RBM5-AS1, STEAP3-AS1, and VPS9D1-AS1 in both tissue and plasma samples from CRC patients to evaluate their potential as diagnostic biomarkers. Selection of these lncRNAs was based on prior studies indicating their dysregulation in CRC and their role in the Wnt/β-catenin signaling pathway, which modulates cell growth, apoptosis, and differentiation.

Materials and methods

This experimental study included 40 plasma samples and 10 tissue samples from CRC patients, alongside an equal number of samples from healthy controls. The expression levels of the lncRNAs and β-catenin were quantified using reverse transcription quantitative polymerase chain reaction (RT-qPCR). The diagnostic performance of these lncRNAs was evaluated through receiver operating characteristic (ROC) curve analysis on Plasma samples, which also facilitated the determination of optimal cutoff values.

Results

The expression of the β-catenin gene was significantly elevated in CRC tissues (6.78-fold increase, p = 0.02) and plasma samples (4.79-fold increase, p < 0.001) compared to controls. Likewise, the expression levels of the lncRNAs were significantly higher in both CRC tissues and plasma samples relative to healthy subjects (p < 0.001). ROC curve analysis revealed robust predictive capabilities for the plasma expression of these lncRNAs, with area under the curve (AUC) values of 0.82 for STEAP3-AS1, 0.94 for VPS9D1-AS1, and 0.83 for RBM5-AS1.

Conclusion

The findings indicate that the expression levels of β-catenin and lncRNAs STEAP3-AS1, VPS9D1-AS1, and RBM5-AS1 are significantly higher in both tissue and plasma samples from CRC patients compared to healthy individuals. Consequently, these lncRNAs may serve as promising biomarkers for CRC diagnosis. However, further studies are needed to validate these findings and explore additional applications.td